Neurocrine Biosciences Inc - NBIX STOCK NEWS

Neurocrine Biosciences (Nasdaq: NBIX) announced the presentation of data from three in vitro studies regarding the dissolution performance of INGREZZA® (valbenazine) capsule contents when mixed with soft foods or delivered via G-tube. Results indicated that crushing the capsules did not affect dissolution performance compared to whole capsules. This is significant for elderly patients with tardive dyskinesia, who may have difficulty swallowing. The data will be presented at the AMDA-PALTC23 Annual Conference from March 9-12 in Tampa, Florida, demonstrating the drug's versatility in administration methods.

Neurocrine Biosciences (NASDAQ: NBIX) will participate in two key investor conferences in Miami this March. The first event is the Barclays Global Healthcare Conference on March 15, 2023, where CEO Kevin Gorman and CFO Matt Abernethy will present at 10:45 a.m. Eastern Time. The second event is the Jefferies Biotech on the Bay Summit on March 16, 2023. Interested parties can access a live webcast of the Barclays presentation via their website, with a replay available for one month after the event.

On March 3, 2023, Neurocrine Biosciences (NASDAQ: NBIX) presented data at the AAGP 2023 Annual Meeting in New Orleans, focusing on the long-term treatment of tardive dyskinesia (TD) in older and elderly patients using INGREZZA (valbenazine). The findings showed that over 80% of patients aged 65+ achieved a clinically meaningful reduction in TD symptoms after 48 weeks of treatment. The study highlighted significant improvements in AIMS total scores and psychiatric stability across both age groups. The results are expected to inform treatment decisions for older adults at risk of TD.

On February 14, 2023, at 12:00 p.m. Eastern Time, Neurocrine Biosciences (NASDAQ: NBIX) will present at the virtual SVB Securities Global Biopharma Conference. The presentation will be led by CEO Kevin Gorman and CFO Matt Abernethy. Interested parties can access the live webcast on the company’s website under the Investors section. A replay will be available approximately one hour post-event and archived for one month. Neurocrine Biosciences focuses on developing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio and 12 mid-to-late-stage clinical programs.

Neurocrine Biosciences reported fourth quarter net product sales of $399 million for INGREZZA, contributing to full-year sales of $1.44 billion. The company projects net product sales guidance for 2023 between $1.67 - $1.77 billion. Key developments include the completion of enrollment in registrational studies for crinecerfont, aimed at treating congenital adrenal hyperplasia, with top-line results expected in the second half of 2023. Financial highlights show a GAAP net income of $89 million for Q4 2022, a significant improvement over the $7 million loss in Q4 2021. Total cash and marketable securities stood at $1.29 billion as of December 31, 2022.

Neurocrine Biosciences (Nasdaq: NBIX) has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for February 6, 2023. The press release will be issued at 4:30 a.m. PT and the call will begin at 5:00 a.m. PT (8:00 a.m. ET). The conference call can be accessed domestically at 866-952-8559 and internationally at 785-424-1743, using conference ID NBIX. A replay will be available approximately an hour after the event and archived for a month. Neurocrine focuses on developing treatments for neurological and endocrine disorders, with several FDA-approved therapies in its portfolio.

Neurocrine Biosciences (Nasdaq: NBIX) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. PT in San Francisco. CEO Kevin Gorman will lead the presentation, which can be accessed via a live webcast on the company's website, www.neurocrine.com. A replay will be available approximately one hour post-event and archived for a month. Neurocrine focuses on developing treatments for neurological and neuroendocrine disorders, with FDA-approved therapies for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids in its portfolio.

Neurocrine Biosciences (Nasdaq: NBIX) has announced that the FDA has accepted its supplemental New Drug Application for valbenazine, targeting chorea associated with Huntington disease, with a PDUFA action date set for August 20, 2023. This sNDA includes data from the KINECT-HD Phase 3 study and ongoing KINECT-HD2 study, involving over 150 patients. Valbenazine aims to provide a new treatment option for the estimated 40,000 adults in the U.S. affected by Huntington disease, characterized by abnormal involuntary movements.

Neurocrine Biosciences (Nasdaq: NBIX) announced that its investigational drug NBI-827104 did not achieve its primary endpoint in the Phase 2 STEAMBOAT study for treating pediatric patients with epileptic encephalopathy characterized by continuous spike-and-wave during sleep. The study aimed to measure the drug's efficacy against placebo in reducing the spike-wave index after 6 weeks. Despite the setback, the drug was well tolerated, and the company plans to analyze the data for future steps in development.